Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.
Finding the right unprofitable companies is difficult, which is why we started StockStory - to help you navigate the market. Keeping that in mind, here are three unprofitable companiesto avoid and some better opportunities instead.
Procore Technologies (PCOR)
Trailing 12-Month GAAP Operating Margin: -9.4%
With a mission to build software for the people that build the world, Procore Technologies (NYSE: PCOR) provides cloud-based software that enables owners, contractors, and other stakeholders to collaborate and manage construction projects from any device.
Why Is PCOR Not Exciting?
- ARR growth averaged a weak 14.8% over the last year, suggesting that competition is pulling some attention away from its software
- Estimated sales growth of 12.9% for the next 12 months implies demand will slow from its two-year trend
- Operating margin expanded by 2.4 percentage points over the last year as it scaled and became more efficient
Procore Technologies’s stock price of $58.93 implies a valuation ratio of 6x forward price-to-sales. Read our free research report to see why you should think twice about including PCOR in your portfolio.
Moderna (MRNA)
Trailing 12-Month GAAP Operating Margin: -158%
Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ: MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases.
Why Should You Sell MRNA?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 46.7% annually over the last two years
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 30.2% annually while its revenue grew
- Free cash flow margin shrank by 178.4 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
Moderna is trading at $54.22 per share, or 10.5x forward price-to-sales. Dive into our free research report to see why there are better opportunities than MRNA.
QuidelOrtho (QDEL)
Trailing 12-Month GAAP Operating Margin: -33.7%
Born from the 2022 merger of Quidel and Ortho Clinical Diagnostics, QuidelOrtho (NASDAQ: QDEL) develops and manufactures diagnostic testing solutions for healthcare providers, from rapid point-of-care tests to complex laboratory instruments and systems.
Why Do We Steer Clear of QDEL?
- Weak constant currency growth over the past two years indicates challenges in maintaining its market share
- Free cash flow margin dropped by 21.9 percentage points over the last five years, implying the company became more capital intensive as competition picked up
- Eroding returns on capital suggest its historical profit centers are aging
At $20.86 per share, QuidelOrtho trades at 9.9x forward P/E. To fully understand why you should be careful with QDEL, check out our full research report (it’s free).
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
